PET scan imaging in oncology

European Journal of Cancer

Volumn 39, Issue 11, 2003, Pages 1525-1534

  Jerusalem, G ^a   Hustinx, R ^b   Beguin, Y ^a   Fillet, G ^a  

^a CHU SART TILMAN   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Fluorodeoxyglucose; Positron emission tomography; Staging

Indexed keywords

FLUORODEOXYGLUCOSE F 18; METHIONINE C 11;

BENIGN TUMOR; BRAIN TUMOR; CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER SCINTISCANNING; CANCER SCREENING; CANCER STAGING; CLINICAL PRACTICE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DIAGNOSTIC PROCEDURE; DIFFERENTIAL DIAGNOSIS; FOLLOW UP; GLIOMA; HUMAN; INTERMETHOD COMPARISON; LUNG NON SMALL CELL CANCER; LUNG TUMOR; LYMPH NODE METASTASIS; MALIGNANT NEOPLASTIC DISEASE; MEDIASTINUM LYMPH NODE; META ANALYSIS; PANCREAS TUMOR; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; TREATMENT INDICATION; TREATMENT OUTCOME; TUMOR LOCALIZATION; TUMOR RECURRENCE; TUMOR VOLUME;

EID: 0038646711     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(03)00374-5     Document Type: Conference Paper

References (63)

1. Jerusalem G., Hustinx R., Beguin Y., Fillet G. The value of positron emission tomography (PET) imaging in disease staging and therapy assessment. Ann. Oncol. 13(Suppl. 4):2002;227-234.
2. Gluecker T.M., Fletcher J.G. CT colonography (virtual colonoscopy) for the detection of colorectal polyps and neoplasms. current status and future developments. Eur. J. Cancer. 38:2002;2070-2078.
3. Miles K.A. Functional computed tomography in oncology. Eur. J. Cancer. 38:2002;2079-2084.
4. Griffiths J.R., Tate A.R., Howe F.A., Stubbs M. Magnetic resonance spectroscopy of cancer - practicalities of multi-centre trials and early results in non-Hodgkin's lymphoma. Eur. J. Cancer. 38:2002;2085-2093.
5. Blomley M.J., Eckersley R.J. Functional ultrasound methods in oncological imaging. Eur. J. Cancer. 38:2002;2108-2115.
6. Padhani A.R. Functional MRI for anticancer therapy assessment. Eur. J. Cancer. 38:2002;2116-2127.
7. Evans J.W., Peters A.M. Gamma camera imaging in malignancy. Eur. J. Cancer. 38:2002;2157-2172.
8. Gupta N., Price P.M., Aboagye E.O. PET for in vivo pharmacokinetic and pharmacodynamic measurements. Eur. J. Cancer. 38:2002;2094-2107.
9. Blasberg R. PET imaging of gene expression. Eur. J. Cancer. 38:2002;2137-2146.
10. Gallagher B.M., Fowler J.S., Gutterson N.I.et al. Metabolic trapping as a principle of radiopharmaceutical design. some factors resposible for the biodistribution of [18F] 2-deoxy-2-fluoro-D-glucose J. Nucl. Med. 19:1978;1154-1161.
11. Yasuda S., Ide M., Fujii H.et al. Application of positron emission tomography imaging to cancer screening. Br. J. Cancer. 83:2000;1607-1611.
12. Gould M.K., Maclean C.C., Kuschner W.G., Rydzak C.E., Owens D.K. Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions. a meta-analysis JAMA. 285:2001;914-924.
13. Gambhir S.S., Shepherd J.E., Shah B.D.et al. Analytical decision model for the cost-effective management of solitary pulmonary nodules. J. Clin. Oncol. 16:1998;2113-2125.
14. Sperti C., Pasquali C., Chierichetti F.et al. Value of 18-fluorodeoxyglucose positron emission tomography in the management of patients with cystic tumors of the pancreas. Ann. Surg. 234:2001;675-680.
15. Sendler A., Avril N., Helmberger H.et al. Preoperative evaluation of pancreatic masses with positron emission tomography using 18F-fluorodeoxyglucose. diagnostic limitations World J. Surg. 24:2000;1121-1129.
16. Kasperk R.K., Riesener K.P., Wilms K., Schumpelick V. Limited value of positron emission tomography in treatment of pancreatic cancer. surgeon's view World J. Surg. 25:2001;1134-1139.
17. Kole A.C., Nieweg O.E., Pruim J.et al. Detection of unknown occult primary tumors using positron emission tomography. Cancer. 82:1998;1160-1166.
18. Aassar O.S., Fischbein N.J., Caputo G.R.et al. Metastatic head and neck cancer. role and usefulness of FDG PET in locating occult primary tumors Radiology. 210:1999;177-181.
19. Greven K.M., Keyes J.W. Jr., Williams D.W.III, McGuirt W.F., Joyce W.T.III Occult primary tumors of the head and neck. lack of benefit from positron emission tomography imaging with 2-[F-18]fluoro-2-deoxy-D-glucose Cancer. 86:1999;114-118.
20. Lassen U., Daugaard G., Eigtved A., Damgaard K., Friberg L. 18F-FDG whole body positron emission tomography (PET) in patients with unknown primary tumours (UPT). Eur. J. Cancer. 35:1999;1076-1082.
21. Bohuslavizki K.H., Klutmann S., Kroger S.et al. FDG PET detection of unknown primary tumors. J. Nucl. Med. 41:2000;816-822.
22. Rades D., Kuhnel G., Wildfang I.et al. Localised disease in cancer of unknown primary (CUP). the value of positron emission tomography (PET) for individual therapeutic management Ann. Oncol. 12:2001;1605-1609.
23. Dwamena B.A., Sonnad S.S., Angobaldo J.O., Wahl R.L. Metastases from non-small cell lung cancer. mediastinal staging in the 1990s - meta-analytic comparison of PET and CT Radiology. 213:1999;530-536.
24. Pieterman R.M., van Putten J.W., Meuzelaar J.J.et al. Preoperative staging of non-small-cell lung cancer with positron-emission tomography. N. Engl. J. Med. 343:2000;254-261.
25. Laking G., Price P. 18-Fluorodeoxyglucose positron emission tomography (FDG-PET) and the staging of early lung cancer. Thorax. 56(Suppl. 2):2001;ii38-ii44.
26. Gambhir S.S., Hoh C.K., Phelps M.E., Madar I., Maddahi J. Decision tree sensitivity analysis for cost-effectiveness of FDG-PET in the staging and management of non-small-cell lung carcinoma. J. Nucl. Med. 37:1996;1428-1436.
27. van Tinteren H., Hoekstra O.S., Smit E.F.et al. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer. the PLUS multicentre randomised trial Lancet. 359:2002;1388-1393.
28. Boyer MJ, Viney R, Fulham M. A randomized trial of conventional staging (CS) in patients (pts) with stage 1 or 2 non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2002, 20, 309a (abstr #1233).
29. Poncelet A.J., Lonneux M., Coche E., Weynand B., Noirhomme P. PET-FDG scan enhances but does not replace preoperative surgical staging in non-small cell lung carcinoma. Eur. J. Cardiothorac. Surg. 20:2001;468-474.
30. Wagner J.D., Schauwecker D., Davidson D.et al. Prospective study of fluorodeoxyglucose-positron emission tomography imaging of lymph node basins in melanoma patients undergoing sentinel node biopsy. J. Clin. Oncol. 17:1999;1508-1515.
31. Acland K.M., Healy C., Calonje E.et al. Comparison of positron emission tomography scanning and sentinel node biopsy in the detection of micrometastases of primary cutaneous malignant melanoma. J. Clin. Oncol. 19:2001;2674-2678.
32. Avril N., Dose J., Janicke F.et al. Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)-fluoro-2-deoxy-D-glucose. J. Natl. Cancer Inst. 88:1996;1204-1209.
33. Flanagan F.L., Dehdashti F., Ogunbiyi O.A., Kodner I.J., Siegel B.A. Utility of FDG-PET for investigating unexplained plasma CEA elevation in patients with colorectal cancer. Ann. Surg. 227:1998;319-323.
34. Simo M., Lomena F., Setoain J.et al. FDG-PET improves the management of patients with suspected recurrence of colorectal cancer. Nucl. Med. Commun. 23:2002;975-982.
35. Huebner R.H., Park K.C., Shepherd J.E.et al. A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer. J. Nucl. Med. 41:2000;1177-1189.
36. Strasberg S.M., Dehdashti F., Siegel B.A., Drebin J.A., Linehan D. Survival of patients evaluated by FDG-PET before hepatic resection for metastatic colorectal carcinoma. a prospective database study Ann. Surg. 233:2001;293-299.
37. Ruers T.J., Langenhoff B.S., Neeleman N.et al. Value of positron emission tomography with [F-18]fluorodeoxyglucose in patients with colorectal liver metastases. a prospective study J. Clin. Oncol. 20:2002;388-395.
38. Kinkel K., Lu Y., Both M., Warren R.S., Thoeni R.F. Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR imaging, PET). a meta-analysis Radiology. 224:2002;748-756.
39. Jerusalem G., Beguin Y., Fassotte M.F.et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood. 94:1999;429-433.
40. Zinzani P.L., Magagnoli M., Chierichetti F.et al. The role of positron emission tomography (PET) in the management of lymphoma patients. Ann. Oncol. 10:1999;1181-1184.
41. Spaepen K., Stroobants S., Dupont P.et al. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non- Hodgkin's lymphoma. is [18F]FDG-PET a valid alternative to conventional diagnostic methods? J. Clin. Oncol. 19:2001;414-419.
42. de Wit M., Bohuslavizki K.H., Buchert R.et al. 18FDG-PET following treatment as valid predictor for disease-free survival in Hodgkin's lymphoma. Ann. Oncol. 12:2001;29-37.
43. Weihrauch M.R., Re D., Scheidhauer K.et al. Thoracic positron emission tomography using (18)F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease. Blood. 98:2001;2930-2934.
44. Jerusalem G., Beguin Y. Commentary on "Positron emission tomography in lymphoma. comparison with computed tomography and gallium-67 single photon emission computed tomography" Clin. Lymphoma. 1:2000;75-76.
45. Ganjoo K.N., Chan R.J., Sharma M., Einhorn L.H. Positron emission tomography scans in the evaluation of postchemotherapy residual masses in patients with seminoma. J. Clin. Oncol. 17:1999;3457-3460.
46. De Santis M., Bokemeyer C., Becherer A.et al. Predictive impact of 2-18fluoro-2-deoxy-D-glucose positron emission tomography for residual postchemotherapy masses in patients with bulky seminoma. J. Clin. Oncol. 19:2001;3740-3744.
47. Kollmannsberger C., Oechsle K., Dohmen B.M.et al. Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography with conventional assessment by computed tomography scans and serum tumor markers for the evaluation of residual masses in patients with nonseminomatous germ cell carcinoma. Cancer. 94:2002;2353-2362.
48. Schechter N.R., Gillenwater A.M., Byers R.M.et al. Can positron emission tomography improve the quality of care for head-and-neck cancer patients? Int. J. Radiat. Oncol. Biol. Phys. 51:2001;4-9.
49. Lonneux M., Lawson G., Ide C.et al. Positron emission tomography with fluorodeoxyglucose for suspected head and neck tumor recurrence in the symptomatic patient. Laryngoscope. 110:2000;1493-1497.
50. Ogawa T., Kanno I., Shishido F.et al. Clinical value of PET with 18F-fluorodeoxyglucose and L-methyl-11C-methionine for diagnosis of recurrent brain tumor and radiation injury. Acta Radiol. 22:1991;197-202.
51. Jerusalem G., Beguin Y., Fassotte M.F.et al. Early detection of relapse by whole-body positron emission tomography (PET) in the follow-up of patients with Hodgkin's disease (HD). Ann. Oncol. 14:2003;123-130.
52. Tyler D.S., Onaitis M., Kherani A.et al. Positron emission tomography scanning in malignant melanoma. Cancer. 89:2000;1019-1025.
53. Mijnhout G.S., Hoekstra O.S., van Tulder M.W., Teule G.J., Deville W.L. Systematic review of the diagnostic accuracy of (18)F-fluorodeoxyglucose positron emission tomography in melanoma patients. Cancer. 91:2001;1530-1542.
54. Hoekstra C.J., Hoekstra O.S., Stroobants S.G.et al. Methods to monitor response to chemotherapy in non-small cell lung cancer with 18F-FDG PET. J. Nucl. Med. 43:2002;1304-1309.
55. Ahuja V., Coleman R.E., Herndon J., Patz E.F. Jr. The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with non small cell lung carcinoma. Cancer. 83:1998;918-924.
56. Vansteenkiste J.F., Stroobants S.G., Dupont P.J.et al. Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer. an analysis of 125 cases. Leuven Lung Cancer Group J. Clin. Oncol. 17:1999;3201-3206.
57. Jerusalem G., Beguin Y., Fassotte M.F.et al. Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma. Haematologica. 85:2000;613-618.
58. Jerusalem G., Beguin Y., Fassotte M.F.et al. [Early treatment evaluation by positron emission tomography]. Med. Hyg. 58:2000;1629-1632, [in French].
59. Young H., Baum R., Cremerius U.et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography. review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group Eur. J. Cancer. 35:1999;1773-1782.
60. Shreve P.D., Grossman H.B., Gross M.D., Wahl R.L. Metastatic prostate cancer. initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose Radiology. 199:1996;751-756.
61. 18F-FDG) for the staging of low grade non-Hodgkin's lymphoma (NHL). Ann. Oncol. 12:2001;825-830.
62. Laking G.R., Price P.M., Sculpher M.J. Assessment of the technology for functional imaging in cancer. Eur. J. Cancer. 38:2002;2194-2199.
63. Cook G.J., Fogelman I., Maisey M.N. Normal physiological and benign pathological variants of 18-fluoro-2-deoxyglucose positron-emission tomography scanning. potential for error in interpretation Semin. Nucl. Med. 26:1996;308-314.